

Drugs@FDA: FDA-Approved Drugs

 [SHARE \(HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=022433\)](https://www.facebook.com/sharer/sharer.php?u=https://www.accessdata.fda.gov/scripts/cder/da/index.cfm?event=overview.process&applno=022433)

 [TWEET \(HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=DRUGS@FDA: FDA-APPROVED DRUGS&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=022433\)](https://twitter.com/intent/tweet/?text=Drugs@FDA: FDA-APPROVED DRUGS&url=https://www.accessdata.fda.gov/scripts/cder/da/index.cfm?event=overview.process&applno=022433)

 [EMAIL \(MAILTO:?SUBJECT=DRUGS@FDA: FDA-APPROVED DRUGS&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=022433\)](mailto:?subject=Drugs@FDA: FDA-APPROVED DRUGS&body=https://www.accessdata.fda.gov/scripts/cder/da/index.cfm?event=overview.process&applno=022433)

[Home \(index.cfm\)](#) | [Previous Page](#)

New Drug Application (NDA): 022433
Company: ASTRAZENECA

 [EMAIL \(MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS%26VARAPPLNO=022433\)](mailto:?subject=Drugs@FDA: FDA APPROVED DRUG PRODUCTS&body=http://www.accessdata.fda.gov/scripts/cder/da/index.cfm?event=overview.process%26varapplno=022433)

- [Medication Guide](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022433s032lbl.pdf#page=34)
(https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022433s032lbl.pdf#page=34)
- [Priority 3 Approval Package](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022433Orig1s015(2).pdf)
([http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022433Orig1s015\(2\).pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022433Orig1s015(2).pdf))
- [Summary Review](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000SumR.pdf)
(http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000SumR.pdf)

Products on NDA 022433							
CSV Excel Print							
Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
BRILINTA	TICAGRELOR	90MG	TABLET;ORAL	Prescription	AB	Yes	Yes
BRILINTA	TICAGRELOR	60MG	TABLET;ORAL	Prescription	AB	Yes	No

Showing 1 to 2 of 2 entries

Approval Date(s) and History, Letters, Labels, Reviews for NDA 022433



Labels for NDA 022433



Therapeutic Equivalents for NDA 022433

